Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H6O |
Molecular Weight | 70.0898 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C=COC=C
InChI
InChIKey=QYKIQEUNHZKYBP-UHFFFAOYSA-N
InChI=1S/C4H6O/c1-3-5-4-2/h3-4H,1-2H2
Vinyl ether (divinyl ether) is a clear colorless liquid with a characteristic odor. Less dense than water. Vapors heavier than air. Toxic by inhalation. Leake and Chen in 1930 demonstrated that vinyl ether possessed anaesthetic properties, and in 1931 a purer and more stable product was prepared in the research laboratories of Merck and Co. by Ruigh and Major and was used as ananaesthetic on dogs by Knoefel, Guedel, and Leake. These investigators found that dogs were more easily anaesthetized by vinyl ether than by chloroform. They also found that the period of recovery was rapid and free from vomiting; moreover, they did not notice any significant pathological effect on the various organs.The first experiments on human beings were conducted in 1933 by Gelfan and Bell. The first extensive account of vinyl ether anaesthesia in man was published in 1934, when Goldschmidt et al. reported having used it in operations in 461 mixed cases. In all these cases vinyl ether appeared to have no undesirable effect on respiration, the circulation, the liver, or the kidneys. Vinyl ether was widely used in Europe and North
America for at least 30 years, until it was replaced by halothane. Vinyl ether was marketed under the name of Vinethine in the United States, Vinesthine in the United Kingdom, and Vinydan in continental Europe. Vinyl ether outlasted many of the inhalation agents introduced in recent
years, and served a very useful purpose until safer,
non-flammable agents, became available in the mid1960s.
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
3 mL single, respiratory Recommended Dose: 3 mL Route: respiratory Route: single Dose: 3 mL Sources: |
unhealthy, 3-9 n = 2210 Health Status: unhealthy Condition: dental extractions Age Group: 3-9 Population Size: 2210 Sources: |
Other AEs: Convulsions... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Convulsions | 5 patients | 3 mL single, respiratory Recommended Dose: 3 mL Route: respiratory Route: single Dose: 3 mL Sources: |
unhealthy, 3-9 n = 2210 Health Status: unhealthy Condition: dental extractions Age Group: 3-9 Population Size: 2210 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
An allyltitanium derived from acrolein 1,2-dicyclohexylethylene acetal and (eta(2)-propene)Ti(O-i-Pr)(2) as a chiral propionaldehyde homoenolate equivalent that reacts with imines with excellent stereoselectivity. An efficient and practical access to optically active gamma-amino carbonyl compounds. | 2001 Apr 18 |
|
Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue. | 2001 Apr-Jun |
|
Effect of fluorinated groups on photooxidative stability of polymeric protectives applied on marble. | 2001 Nov-Dec |
|
Reactive brominating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens: disparate utilization of sodium halides in the production of alpha-halo fatty aldehydes. | 2002 Feb 15 |
|
C-phosphanyl-C-chloroiminium salts as electrophilic carbene synthetic equivalents. | 2002 Oct 7 |
|
Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. | 2004 Apr |
|
Catalytic asymmetric claisen rearrangement in natural product synthesis: synthetic studies toward (-)-xeniolide F. | 2005 Dec 8 |
|
Hidden stereospecificity in the biosynthesis of divinyl ether fatty acids. | 2005 Feb |
|
Hydration of vinyl ether groups by unsaturated glycoside hydrolases and their role in bacterial pathogenesis. | 2007 Dec |
|
Shotgun lipidomics identifies a paired rule for the presence of isomeric ether phospholipid molecular species. | 2007 Dec 26 |
|
Characterization of a divinyl ether biosynthetic pathway specifically associated with pathogenesis in tobacco. | 2007 Jan |
|
The investigation of protein adsorption behaviors on different functionalized polymers films. | 2007 Jun |
|
Reduction of divinyl ether-containing polyunsaturated fatty acids in transgenic potato plants. | 2007 Mar |
|
Organocatalytic claisen rearrangement: theory and experiment. | 2007 May 25 |
|
Separation of intact plasmalogens and all other phospholipids by a single run of high-performance liquid chromatography. | 2007 Nov 1 |
|
Dipole-LUMO/dipolarophile-HOMO controlled asymmetric cycloadditions of carbonyl ylides catalyzed by chiral Lewis acids. | 2007 Oct 11 |
|
How to improve the storage stability of aqueous polymeric film coatings. | 2008 Feb 18 |
|
Sheddable coatings for long-circulating nanoparticles. | 2008 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20781128
In the blood, anaesthesia is produced with a remarkably small concentration; in dogs this is 28 mg per 100 ccm.
Route of Administration:
Respiratory
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN01AA02
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
||
|
WHO-ATC |
N01AA02
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
109-93-3
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
Divinyl ether
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105883
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
3645
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
2H2T044E11
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
100000076712
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
DTXSID5074555
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
DB13690
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
C100195
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
203-720-5
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
8024
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
SUB15697MIG
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | |||
|
m4697
Created by
admin on Fri Dec 15 14:57:57 GMT 2023 , Edited by admin on Fri Dec 15 14:57:57 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD